Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AtheroGenics, Inc.{AGIX}-nasdaq -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (27)	2/19/2001 11:46:29 AM
From: keokalani'nui	Read Replies (1) \| Respond to of 332

Some notes from the HQ (underwiter) CC: Re 1067-- The P2b restensosis trial is partnered with SGP. Up to $189m milestones plus mid-teen royalty. Small moledule inhibitor of the 'gene set' that normally responds TNF/receptor binding. It is synthetic, given 1 dose/day. Brought it from discovery to IND in 27 mos. Indications are CAD, atherosclerosis, RA. It is also a 50-60% cholesterol lowering agent, and blocks LDL from becoming oxidized which contributes to CAD--so 3 vascualar protecting properties (anti-VCAM1, cholesterol lowering and anti-oxidant). Numerous animal studies. Tested 1 year in monkies. No tox given orally, daily. Showed 80% reduction in cholesterol, LDL up 30%, no evidence of atheroscerlosis in higher doses, some in lower doses. At 150mg/kg, the animals were blindly read as 'normal' by Quintiles (cross directorship here, incidentally). Animals livers were normal after 1 year. P2 dosing finished. (missed dose mentioned, sorry). 6 weeks on, 6 weeks follow up. Reporting 4/01. Safety OK so far. Endpoint is 40-50% reduction in reclosure rate. Re:4207 100% owned. RA. Pre-IND. Into clinic '01. Partner after P1 or P2. Company plans on keeping CF and transplantation. Prospectus suggests multiple drug opportunites from understanding intracellular signalling based on original inflammatory response. --Wilder Not touting, just contributing.